Related Experiment Video
Updated: Sep 7, 2025
09:49
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10.1K
Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review
Angela Y Jia1, Rojano Kashani2, Nicholas G Zaorsky2
1Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.
Practical Radiation Oncology
|June 18, 2022
Summary
Lutetium-177 prostate-specific membrane antigen (PSMA) offers a promising targeted radionuclide therapy for prostate cancer. This review covers its application, from research to standard care, emphasizing multidisciplinary team involvement.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Prostate-specific membrane antigen (PSMA) is a transmembrane protein highly expressed in prostate cancer.
- PSMA is a key biomarker for targeted therapies in prostate cancer management.
Purpose of the Study:
- To review the background, clinical data, patient selection, side effects, and resource requirements for delivering lutetium-177 PSMA therapy.
- To discuss the potential transition of lutetium-177 PSMA from research to standard of care.
Main Methods:
- Review of existing literature on lutetium-177 PSMA therapy.
- Analysis of clinical data, patient selection criteria, and potential side effects.
- Assessment of necessary resources for therapy delivery.
Main Results:
- Lutetium-177 PSMA demonstrates potential as a targeted radionuclide therapeutic for prostate cancer.
- Successful delivery requires understanding of radiobiology, physics, and multidisciplinary collaboration.
Conclusions:
- Radiation oncologists and medical physicists are crucial for the delivery and monitoring of lutetium-177 PSMA therapy.
- Effective implementation necessitates a comprehensive, multidisciplinary approach for optimal patient outcomes.
